文献速递肿瘤 PET/CT

PSMA-PET/CT 对前列腺癌初始分期临床决策的影响

The impact of PSMA-PET/CT on clinical decision-making in primary staging of prostate cancer.
PubMed 文献 · EJNMMI Res · 2026-06-30

PSMA-PET/CT 使 65 例(22.6%)患者的临床管理发生改变,其中重大改变 31 例(10.8%)、中等改变 28 例(9.9%)、轻微改变 6 例(2.1%),高危患者改变更频繁(24.6% 对 15.3%)。

要点

  • PSMA-PET/CT 使约四分之一初始分期患者的管理决策发生改变。
  • 高危患者管理改变频率(24.6%)高于中危患者(15.3%)。
  • PSMA-PET/CT 在 94 例患者中检出病灶,仅 6 例由常规影像单独阳性。

核心结论

  • PSMA-PET/CT 提供可操作信息,使约四分之一初始分期患者临床管理发生改变,高危疾病影响最大。

研究设计与样本

  • 所有患者均在 90 天内接受 [18F]PSMA-1007 PET/CT、CT 和骨显像检查。
  • 通过比较仅基于常规影像的治疗决策与结合 PSMA-PET/CT 后的决策评估管理改变。

主要发现

  • 287 例患者中 59 例(21%)为中危、228 例(79%)为高危。
  • 187 例(65%)所有影像学检查均阴性,100 例(35%)阳性。
  • PSMA-PET/CT 在 94 例患者中检出病灶,仅 6 例患者常规影像单独阳性。
  • 65 例(22.6%)临床管理改变,包括重大改变 31 例(10.8%)、中等改变 28 例(9.9%)、轻微改变 6 例(2.1%)。
  • 在 PSMA-PET/CT 阳性患者(n=94)中,32.0% 发生重大、29.8% 中等、5.2% 轻微治疗调整。

关键数值与推荐

  • 管理改变分类:重大改变为治愈性与非治愈性治疗意图之间的转换。
  • 中等改变为修改手术或放疗计划但不改变总体治疗意图。
  • 轻微改变为额外检查或微小调整导致治疗延迟,但不改变意图或方式。
  • 高危患者管理改变频率为 24.6%,中危患者为 15.3%。

临床怎么用

  • 支持将 PSMA-PET/CT 整合入常规分期,以实现更精准和个体化的治疗计划。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Accurate staging is essential for optimal management of prostate cancer. Conventional imaging with computed tomography and bone scintigraphy has limited sensitivity and specificity, particularly for small-volume disease. Prostate-specific membrane antigen positron emission tomography/computed tomography (PSMA-PET/CT) has emerged as a more sensitive modality, but its impact on clinical decision-making in primary staging remains to be fully defined. In this retrospective single-center study, we evaluated the impact of PSMA-PET/CT on treatment strategies compared with conventional imaging in patients with intermediate- and high-risk prostate cancer at Skåne University Hospital, Sweden, between October 2020 and December 2022. All patients underwent [18F]PSMA-1007 PET/CT, computed tomography and bone scintigraphy within 90 days. Management decisions were assessed by comparing treatment decisions based on conventional imaging alone with those incorporating PSMA-PET/CT findings, and were classified as major (shift between curative and non-curative treatment intent), medium (modification of surgical or radiotherapy plans without altering overall treatment intent), and minor (additional investigations or minor adjustments resulting in treatment delay without change of intent or modality). RESULTS: A total of 287 consecutive patients were included, of whom 59 (21%) had intermediate-risk and 228 (79%) high-risk disease. Overall, 187 patients (65%) had negative findings on all imaging modalities, while 100 (35%) had positive findings. PSMA-PET/CT identified lesions in 94 patients, whereas only 6 patients had positive findings exclusively on conventional imaging. PSMA-PET/CT led to a change in clinical management in 65 patients (22.6%), including major changes in 31 (10.8%), medium changes in 28 (9.9%), and minor changes in 6 (2.1%). Among patients with positive PSMA-PET/CT findings (n = 94), 32.0% experienced major, 29.8% medium and 5.2% minor treatment modifications. Management changes were more frequent in high-risk patients (24.6%) compared to intermediate-risk patients (15.3%). CONCLUSION: PSMA-PET/CT provides actionable information that leads to changes in clinical management in approximately one in four patients undergoing primary staging of prostate cancer, with the greatest impact observed in high-risk disease. These findings support the integration of PSMA-PET/CT into routine staging to enable more precise and individualized treatment planning.

来源:EJNMMI Res,查看原文。版权归原作者所有。

引用

  1. Ingvar J, Green R, Trägårdh E, et al. The impact of PSMA-PET/CT on clinical decision-making in primary staging of prostate cancer. EJNMMI Res. 2026. PMID: 42380714. doi:10.1186/s13550-026-01480-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。